Monash Health, in collaboration with Monash University, has administered Australia’s first CAR (Chimeric Antigen Receptor) T-cell therapy treatment for lupus. Previously used in oncology to target certain blood cancers, CAR T-cell therapy is now being explored as a treatment pathway for autoimmune diseases.
The therapy involves modifying a patient’s own immune cells to recognize and eliminate harmful immune responses. In this case, it was used to treat 32-year-old Lani Watson, who was diagnosed with systemic lupus erythematosus (SLE) in mid-2022. Following the treatment, Watson entered remission and was able to discontinue her previous immunosuppressive medications.
Lupus is a chronic condition in which the body’s immune system mistakenly attacks its own tissues, potentially affecting skin, joints, kidneys, and other organs. It is more commonly diagnosed in females, particularly between the ages of 20 and 40.
Associate Professor Alberta Hoi, Consultant Rheumatologist at Monash Health and clinical lead on the trial, noted that the response to the treatment was positive. Professor Jake Shortt, Clinical Director of Haematology, emphasized that the infrastructure at Monash Health supports further development in treating both cancer and autoimmune conditions.
This case is part of a larger effort to evaluate the safety and potential long-term benefits of CAR T-cell therapy beyond its current applications. While results from this single case are encouraging, as always, further study is needed to determine broader clinical outcomes.
